GLIPR1L2

Across TCGA pan-cancer cohorts, GLIPR1L2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLIPR1L2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GLIPR1L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLIPR1L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, SKCM, and UCEC are the cancer types where GLIPR1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.250	0.692	.009	18	view →
SKCM	OS	Median	IV	0.415	0.861	.014	15	view →
UCEC	DFS	Median	All	0.955	0.626	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GLIPR1L2–OV (OS)

Open the OV breakdown →